Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants.
Identifieur interne : 000363 ( Main/Exploration ); précédent : 000362; suivant : 000364Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants.
Auteurs : François Le Mauff [France, Canada] ; Geneviève Mercier [Canada] ; Philippe Chan [France] ; Carole Burel [France] ; David Vaudry [France] ; Muriel Bardor [France] ; Louis-Philippe Vézina [Canada] ; Manon Couture [Canada] ; Patrice Lerouge [France] ; Nathalie Landry [Canada]Source :
- Plant biotechnology journal [ 1467-7652 ] ; 2015.
Descripteurs français
- KwdFr :
- Données de séquences moléculaires (MeSH), Expression des gènes (MeSH), Glycoprotéine hémagglutinine du virus influenza (composition chimique), Glycoprotéine hémagglutinine du virus influenza (immunologie), Glycosylation (MeSH), Grippe humaine (prévention et contrôle), Humains (MeSH), Microdomaines membranaires (MeSH), Phospholipides (composition chimique), Polyosides (composition chimique), Protéines recombinantes (MeSH), Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H5N1 du virus de la grippe A (immunologie), Sphingolipides (composition chimique), Séquence d'acides aminés (MeSH), Tabac (génétique), Tabac (métabolisme), Vaccins antigrippaux (immunologie), Vaccins à pseudo-particules virales (immunologie), Végétaux génétiquement modifiés (MeSH), Épitopes (composition chimique), Épitopes (immunologie).
- MESH :
- composition chimique : Glycoprotéine hémagglutinine du virus influenza, Phospholipides, Polyosides, Sphingolipides, Épitopes.
- génétique : Tabac.
- immunologie : Glycoprotéine hémagglutinine du virus influenza, Sous-type H1N1 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux, Vaccins à pseudo-particules virales, Épitopes.
- métabolisme : Tabac.
- prévention et contrôle : Grippe humaine.
- Données de séquences moléculaires, Expression des gènes, Glycosylation, Humains, Microdomaines membranaires, Protéines recombinantes, Séquence d'acides aminés, Végétaux génétiquement modifiés.
English descriptors
- KwdEn :
- Amino Acid Sequence (MeSH), Epitopes (chemistry), Epitopes (immunology), Gene Expression (MeSH), Glycosylation (MeSH), Hemagglutinin Glycoproteins, Influenza Virus (chemistry), Hemagglutinin Glycoproteins, Influenza Virus (immunology), Humans (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H5N1 Subtype (immunology), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Membrane Microdomains (MeSH), Molecular Sequence Data (MeSH), Phospholipids (chemistry), Plants, Genetically Modified (MeSH), Polysaccharides (chemistry), Recombinant Proteins (MeSH), Sphingolipids (chemistry), Tobacco (genetics), Tobacco (metabolism), Vaccines, Virus-Like Particle (immunology).
- MESH :
- chemical , chemistry : Epitopes, Hemagglutinin Glycoproteins, Influenza Virus, Phospholipids, Polysaccharides, Sphingolipids.
- chemical , immunology : Epitopes, Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Vaccines, Virus-Like Particle.
- genetics : Tobacco.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H5N1 Subtype.
- metabolism : Tobacco.
- prevention & control : Influenza, Human.
- Amino Acid Sequence, Gene Expression, Glycosylation, Humans, Membrane Microdomains, Molecular Sequence Data, Plants, Genetically Modified, Recombinant Proteins.
Abstract
Influenza virus-like particles (VLPs) are noninfectious particles resembling the influenza virus representing a promising vaccine alternative to inactivated influenza virions as antigens. Medicago inc. has developed a plant-based VLP manufacturing platform allowing the large-scale production of GMP-grade influenza VLPs. In this article, we report on the biochemical compositions of these plant-based influenza candidate vaccines, more particularly the characterization of the N-glycan profiles of the viral haemagglutinins H1 and H5 proteins as well as the tobacco-derived lipid content and residual impurities. Mass spectrometry analyses showed that all N-glycosylation sites of the extracellular domain of the recombinant haemagglutinins carry plant-specific complex-type N-glycans having core α(1,3)-fucose, core β(1,2)-xylose epitopes and Lewis(a) extensions. Previous phases I and II clinical studies have demonstrated that no hypersensibility nor induction of IgG or IgE directed against these glycans was observed. In addition, this article showed that the plant-made influenza vaccines are highly pure VLPs preparations while detecting no protein contaminants coming either from Agrobacterium or from the enzymes used for the enzyme-assisted extraction process. In contrast, VLPs contain few host cell proteins and glucosylceramides associated with plant lipid rafts. Identification of such raft markers, together with the type of host cell impurity identified, confirmed that the mechanism of VLP formation in planta is similar to the natural process of influenza virus assembly in mammals.
DOI: 10.1111/pbi.12301
PubMed: 25523794
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants.</title><author><name sortKey="Le Mauff, Francois" sort="Le Mauff, Francois" uniqKey="Le Mauff F" first="François" last="Le Mauff">François Le Mauff</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Medicago inc., Québec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago inc., Québec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Mercier, Genevieve" sort="Mercier, Genevieve" uniqKey="Mercier G" first="Geneviève" last="Mercier">Geneviève Mercier</name><affiliation wicri:level="1"><nlm:affiliation>Medicago inc., Québec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago inc., Québec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Chan, Philippe" sort="Chan, Philippe" uniqKey="Chan P" first="Philippe" last="Chan">Philippe Chan</name><affiliation wicri:level="1"><nlm:affiliation>PISSARO Proteomic Platform, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>PISSARO Proteomic Platform, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation></author><author><name sortKey="Burel, Carole" sort="Burel, Carole" uniqKey="Burel C" first="Carole" last="Burel">Carole Burel</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation></author><author><name sortKey="Vaudry, David" sort="Vaudry, David" uniqKey="Vaudry D" first="David" last="Vaudry">David Vaudry</name><affiliation wicri:level="1"><nlm:affiliation>PISSARO Proteomic Platform, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>PISSARO Proteomic Platform, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation></author><author><name sortKey="Bardor, Muriel" sort="Bardor, Muriel" uniqKey="Bardor M" first="Muriel" last="Bardor">Muriel Bardor</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation></author><author><name sortKey="Vezina, Louis Philippe" sort="Vezina, Louis Philippe" uniqKey="Vezina L" first="Louis-Philippe" last="Vézina">Louis-Philippe Vézina</name><affiliation wicri:level="1"><nlm:affiliation>Medicago inc., Québec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago inc., Québec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Couture, Manon" sort="Couture, Manon" uniqKey="Couture M" first="Manon" last="Couture">Manon Couture</name><affiliation wicri:level="1"><nlm:affiliation>Medicago inc., Québec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago inc., Québec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Lerouge, Patrice" sort="Lerouge, Patrice" uniqKey="Lerouge P" first="Patrice" last="Lerouge">Patrice Lerouge</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation></author><author><name sortKey="Landry, Nathalie" sort="Landry, Nathalie" uniqKey="Landry N" first="Nathalie" last="Landry">Nathalie Landry</name><affiliation wicri:level="1"><nlm:affiliation>Medicago inc., Québec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago inc., Québec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25523794</idno><idno type="pmid">25523794</idno><idno type="doi">10.1111/pbi.12301</idno><idno type="wicri:Area/Main/Corpus">000367</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000367</idno><idno type="wicri:Area/Main/Curation">000367</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000367</idno><idno type="wicri:Area/Main/Exploration">000367</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants.</title><author><name sortKey="Le Mauff, Francois" sort="Le Mauff, Francois" uniqKey="Le Mauff F" first="François" last="Le Mauff">François Le Mauff</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Medicago inc., Québec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago inc., Québec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Mercier, Genevieve" sort="Mercier, Genevieve" uniqKey="Mercier G" first="Geneviève" last="Mercier">Geneviève Mercier</name><affiliation wicri:level="1"><nlm:affiliation>Medicago inc., Québec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago inc., Québec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Chan, Philippe" sort="Chan, Philippe" uniqKey="Chan P" first="Philippe" last="Chan">Philippe Chan</name><affiliation wicri:level="1"><nlm:affiliation>PISSARO Proteomic Platform, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>PISSARO Proteomic Platform, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation></author><author><name sortKey="Burel, Carole" sort="Burel, Carole" uniqKey="Burel C" first="Carole" last="Burel">Carole Burel</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation></author><author><name sortKey="Vaudry, David" sort="Vaudry, David" uniqKey="Vaudry D" first="David" last="Vaudry">David Vaudry</name><affiliation wicri:level="1"><nlm:affiliation>PISSARO Proteomic Platform, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>PISSARO Proteomic Platform, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation></author><author><name sortKey="Bardor, Muriel" sort="Bardor, Muriel" uniqKey="Bardor M" first="Muriel" last="Bardor">Muriel Bardor</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation></author><author><name sortKey="Vezina, Louis Philippe" sort="Vezina, Louis Philippe" uniqKey="Vezina L" first="Louis-Philippe" last="Vézina">Louis-Philippe Vézina</name><affiliation wicri:level="1"><nlm:affiliation>Medicago inc., Québec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago inc., Québec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Couture, Manon" sort="Couture, Manon" uniqKey="Couture M" first="Manon" last="Couture">Manon Couture</name><affiliation wicri:level="1"><nlm:affiliation>Medicago inc., Québec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago inc., Québec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Lerouge, Patrice" sort="Lerouge, Patrice" uniqKey="Lerouge P" first="Patrice" last="Lerouge">Patrice Lerouge</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan</wicri:regionArea><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion><wicri:noRegion>Mont-Saint-Aignan</wicri:noRegion></affiliation></author><author><name sortKey="Landry, Nathalie" sort="Landry, Nathalie" uniqKey="Landry N" first="Nathalie" last="Landry">Nathalie Landry</name><affiliation wicri:level="1"><nlm:affiliation>Medicago inc., Québec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago inc., Québec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author></analytic><series><title level="j">Plant biotechnology journal</title><idno type="eISSN">1467-7652</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence (MeSH)</term><term>Epitopes (chemistry)</term><term>Epitopes (immunology)</term><term>Gene Expression (MeSH)</term><term>Glycosylation (MeSH)</term><term>Hemagglutinin Glycoproteins, Influenza Virus (chemistry)</term><term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza A Virus, H5N1 Subtype (immunology)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Membrane Microdomains (MeSH)</term><term>Molecular Sequence Data (MeSH)</term><term>Phospholipids (chemistry)</term><term>Plants, Genetically Modified (MeSH)</term><term>Polysaccharides (chemistry)</term><term>Recombinant Proteins (MeSH)</term><term>Sphingolipids (chemistry)</term><term>Tobacco (genetics)</term><term>Tobacco (metabolism)</term><term>Vaccines, Virus-Like Particle (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Données de séquences moléculaires (MeSH)</term><term>Expression des gènes (MeSH)</term><term>Glycoprotéine hémagglutinine du virus influenza (composition chimique)</term><term>Glycoprotéine hémagglutinine du virus influenza (immunologie)</term><term>Glycosylation (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Humains (MeSH)</term><term>Microdomaines membranaires (MeSH)</term><term>Phospholipides (composition chimique)</term><term>Polyosides (composition chimique)</term><term>Protéines recombinantes (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Sous-type H5N1 du virus de la grippe A (immunologie)</term><term>Sphingolipides (composition chimique)</term><term>Séquence d'acides aminés (MeSH)</term><term>Tabac (génétique)</term><term>Tabac (métabolisme)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins à pseudo-particules virales (immunologie)</term><term>Végétaux génétiquement modifiés (MeSH)</term><term>Épitopes (composition chimique)</term><term>Épitopes (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Epitopes</term><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Phospholipids</term><term>Polysaccharides</term><term>Sphingolipids</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Epitopes</term><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Influenza Vaccines</term><term>Vaccines, Virus-Like Particle</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term><term>Phospholipides</term><term>Polyosides</term><term>Sphingolipides</term><term>Épitopes</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Tobacco</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Tabac</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H5N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Vaccins à pseudo-particules virales</term><term>Épitopes</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H5N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Tobacco</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Tabac</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Gene Expression</term><term>Glycosylation</term><term>Humans</term><term>Membrane Microdomains</term><term>Molecular Sequence Data</term><term>Plants, Genetically Modified</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Données de séquences moléculaires</term><term>Expression des gènes</term><term>Glycosylation</term><term>Humains</term><term>Microdomaines membranaires</term><term>Protéines recombinantes</term><term>Séquence d'acides aminés</term><term>Végétaux génétiquement modifiés</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza virus-like particles (VLPs) are noninfectious particles resembling the influenza virus representing a promising vaccine alternative to inactivated influenza virions as antigens. Medicago inc. has developed a plant-based VLP manufacturing platform allowing the large-scale production of GMP-grade influenza VLPs. In this article, we report on the biochemical compositions of these plant-based influenza candidate vaccines, more particularly the characterization of the N-glycan profiles of the viral haemagglutinins H1 and H5 proteins as well as the tobacco-derived lipid content and residual impurities. Mass spectrometry analyses showed that all N-glycosylation sites of the extracellular domain of the recombinant haemagglutinins carry plant-specific complex-type N-glycans having core α(1,3)-fucose, core β(1,2)-xylose epitopes and Lewis(a) extensions. Previous phases I and II clinical studies have demonstrated that no hypersensibility nor induction of IgG or IgE directed against these glycans was observed. In addition, this article showed that the plant-made influenza vaccines are highly pure VLPs preparations while detecting no protein contaminants coming either from Agrobacterium or from the enzymes used for the enzyme-assisted extraction process. In contrast, VLPs contain few host cell proteins and glucosylceramides associated with plant lipid rafts. Identification of such raft markers, together with the type of host cell impurity identified, confirmed that the mechanism of VLP formation in planta is similar to the natural process of influenza virus assembly in mammals. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25523794</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1467-7652</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Plant biotechnology journal</Title><ISOAbbreviation>Plant Biotechnol J</ISOAbbreviation></Journal><ArticleTitle>Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants.</ArticleTitle><Pagination><MedlinePgn>717-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pbi.12301</ELocationID><Abstract><AbstractText>Influenza virus-like particles (VLPs) are noninfectious particles resembling the influenza virus representing a promising vaccine alternative to inactivated influenza virions as antigens. Medicago inc. has developed a plant-based VLP manufacturing platform allowing the large-scale production of GMP-grade influenza VLPs. In this article, we report on the biochemical compositions of these plant-based influenza candidate vaccines, more particularly the characterization of the N-glycan profiles of the viral haemagglutinins H1 and H5 proteins as well as the tobacco-derived lipid content and residual impurities. Mass spectrometry analyses showed that all N-glycosylation sites of the extracellular domain of the recombinant haemagglutinins carry plant-specific complex-type N-glycans having core α(1,3)-fucose, core β(1,2)-xylose epitopes and Lewis(a) extensions. Previous phases I and II clinical studies have demonstrated that no hypersensibility nor induction of IgG or IgE directed against these glycans was observed. In addition, this article showed that the plant-made influenza vaccines are highly pure VLPs preparations while detecting no protein contaminants coming either from Agrobacterium or from the enzymes used for the enzyme-assisted extraction process. In contrast, VLPs contain few host cell proteins and glucosylceramides associated with plant lipid rafts. Identification of such raft markers, together with the type of host cell impurity identified, confirmed that the mechanism of VLP formation in planta is similar to the natural process of influenza virus assembly in mammals. </AbstractText><CopyrightInformation>© 2014 Society for Experimental Biology, Association of Applied Biologists and John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le Mauff</LastName><ForeName>François</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicago inc., Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercier</LastName><ForeName>Geneviève</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medicago inc., Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>PISSARO Proteomic Platform, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burel</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaudry</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>PISSARO Proteomic Platform, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bardor</LastName><ForeName>Muriel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vézina</LastName><ForeName>Louis-Philippe</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Medicago inc., Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couture</LastName><ForeName>Manon</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medicago inc., Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerouge</LastName><ForeName>Patrice</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratoire Glyco-MEV EA 4358, Institut de Recherche et d'Innovation Biomédicale, Normandie Université, Mont-Saint-Aignan, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landry</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medicago inc., Québec, QC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Plant Biotechnol J</MedlineTA><NlmUniqueID>101201889</NlmUniqueID><ISSNLinking>1467-7644</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011134">Polysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013107">Sphingolipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021962" MajorTopicYN="N">Membrane Microdomains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030821" MajorTopicYN="N">Plants, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011134" MajorTopicYN="N">Polysaccharides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013107" MajorTopicYN="N">Sphingolipids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014026" MajorTopicYN="N">Tobacco</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">N-glycosylation</Keyword><Keyword MajorTopicYN="N">haemagglutinin</Keyword><Keyword MajorTopicYN="N">lipid raft</Keyword><Keyword MajorTopicYN="N">plant</Keyword><Keyword MajorTopicYN="N">virus-like particles</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25523794</ArticleId><ArticleId IdType="doi">10.1111/pbi.12301</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Le Mauff, Francois" sort="Le Mauff, Francois" uniqKey="Le Mauff F" first="François" last="Le Mauff">François Le Mauff</name></noRegion><name sortKey="Bardor, Muriel" sort="Bardor, Muriel" uniqKey="Bardor M" first="Muriel" last="Bardor">Muriel Bardor</name><name sortKey="Burel, Carole" sort="Burel, Carole" uniqKey="Burel C" first="Carole" last="Burel">Carole Burel</name><name sortKey="Chan, Philippe" sort="Chan, Philippe" uniqKey="Chan P" first="Philippe" last="Chan">Philippe Chan</name><name sortKey="Lerouge, Patrice" sort="Lerouge, Patrice" uniqKey="Lerouge P" first="Patrice" last="Lerouge">Patrice Lerouge</name><name sortKey="Vaudry, David" sort="Vaudry, David" uniqKey="Vaudry D" first="David" last="Vaudry">David Vaudry</name></country><country name="Canada"><noRegion><name sortKey="Le Mauff, Francois" sort="Le Mauff, Francois" uniqKey="Le Mauff F" first="François" last="Le Mauff">François Le Mauff</name></noRegion><name sortKey="Couture, Manon" sort="Couture, Manon" uniqKey="Couture M" first="Manon" last="Couture">Manon Couture</name><name sortKey="Landry, Nathalie" sort="Landry, Nathalie" uniqKey="Landry N" first="Nathalie" last="Landry">Nathalie Landry</name><name sortKey="Mercier, Genevieve" sort="Mercier, Genevieve" uniqKey="Mercier G" first="Geneviève" last="Mercier">Geneviève Mercier</name><name sortKey="Vezina, Louis Philippe" sort="Vezina, Louis Philippe" uniqKey="Vezina L" first="Louis-Philippe" last="Vézina">Louis-Philippe Vézina</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/AgrobacTransV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000363 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000363 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= AgrobacTransV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25523794
|texte= Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25523794" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AgrobacTransV1
| This area was generated with Dilib version V0.6.38. |  |